Profile data is unavailable for this security.
About the company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
- Revenue in USD (TTM)3.58bn
- Net income in USD1.48bn
- Incorporated1998
- Employees2.68k
- LocationGenmab A/SCarl Jacobsens Vej 30VALBY 2500DenmarkDNK
- Phone+45 70202728
- Fax+45 70202729
- Websitehttps://www.genmab.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tempus AI Inc | 1.11bn | -203.88m | 9.94bn | 2.40k | -- | 19.57 | -- | 8.99 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 10.14bn | 3.10k | 127.67 | 5.02 | 55.18 | 8.34 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.87bn | 528.00 | -- | 17.37 | -- | 14.68 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| ICON PLC | 8.10bn | 599.48m | 11.04bn | 39.80k | 19.54 | 1.18 | 11.17 | 1.36 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Summit Therapeutics Inc | 0.00 | -921.62m | 11.35bn | 159.00 | -- | 59.05 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Exelixis Inc | 2.29bn | 677.90m | 11.52bn | 1.15k | 18.09 | 5.33 | 16.28 | 5.04 | 2.38 | 2.38 | 8.00 | 8.06 | 0.7913 | 3.19 | 7.90 | 1,994,959.00 | 23.44 | 9.51 | 27.03 | 10.77 | 96.63 | 96.32 | 29.63 | 15.61 | 3.68 | -- | 0.00 | 0.00 | 18.49 | 17.51 | 150.89 | 10.18 | 17.25 | -- |
| Medpace Holdings Inc | 2.53bn | 451.12m | 12.65bn | 6.20k | 29.17 | 27.50 | 26.41 | 5.00 | 15.29 | 15.29 | 85.68 | 16.22 | 1.24 | -- | 7.24 | -- | 22.13 | 18.52 | 55.42 | 37.53 | 30.06 | 29.60 | 17.83 | 17.15 | -- | -- | -- | -- | 19.97 | 22.27 | 11.57 | 25.50 | 0.0102 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 13.19bn | 12.00 | -- | 2,714.45 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
| Ionis Pharmaceuticals Inc | 966.96m | -256.34m | 13.65bn | 1.07k | -- | 21.98 | -- | 14.12 | -1.71 | -1.71 | 5.87 | 3.84 | 0.3163 | 0.6054 | 45.47 | 904,542.60 | -8.39 | -11.71 | -10.45 | -13.72 | 98.78 | 98.42 | -26.51 | -44.15 | 2.78 | -- | 0.7414 | -- | -10.48 | -8.88 | -23.92 | -- | 7.94 | -- |
| Revolution Medicines Inc | 0.00 | -960.98m | 18.55bn | 809.00 | -- | 11.40 | -- | -- | -5.18 | -5.18 | 0.00 | 8.42 | 0.00 | -- | -- | 0.00 | -47.87 | -28.38 | -52.53 | -30.68 | -- | -- | -- | -1,324.37 | -- | -- | 0.1384 | -- | -100.00 | -- | -37.52 | -- | 31.83 | -- |
| Exact Sciences Corp | 3.08bn | -986.58m | 19.72bn | 6.90k | -- | 7.83 | -- | 6.40 | -5.32 | -5.32 | 16.43 | 13.20 | 0.4873 | 6.67 | 10.80 | 446,671.40 | -15.60 | -11.29 | -17.40 | -12.38 | 67.37 | 71.21 | -32.01 | -30.90 | 2.44 | -- | 0.4833 | -- | 10.37 | 25.78 | -403.97 | -- | 0.9474 | -- |
| Genmab A/S - ADR | 3.58bn | 1.48bn | 19.86bn | 2.68k | 13.02 | 3.28 | 12.83 | 5.54 | 2.35 | 2.35 | 5.68 | 9.34 | 0.5535 | 16.68 | 3.60 | 1,335,838.00 | 22.89 | 17.70 | 25.72 | 19.07 | 94.27 | -- | 41.35 | 35.77 | 6.01 | -- | 0.0241 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Orbis Investment Management Ltd.as of 30 Sep 2025 | 11.08m | 1.73% |
| AllianceBernstein LPas of 30 Sep 2025 | 10.95m | 1.71% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 3.82m | 0.59% |
| Arrowstreet Capital LPas of 30 Sep 2025 | 3.64m | 0.57% |
| Harding Loevner LPas of 30 Sep 2025 | 3.48m | 0.54% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 2.82m | 0.44% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.61m | 0.41% |
| First Trust Advisors LPas of 30 Sep 2025 | 1.69m | 0.26% |
| Parametric Portfolio Associates LLCas of 30 Sep 2025 | 1.58m | 0.25% |
| Two Sigma Advisers LPas of 30 Sep 2025 | 1.43m | 0.22% |
